New research proposes a novel mechanism for how tumors sidestep the immune system in patients with intracranial tumors.
The FDA based its approval on findings from a single-arm phase 2 study, in which researchers treated 68 patients with iobenguane I 131 intravenous injection.
EGFR-amplified tumors had a high rate of response.
Researchers enrolled 66 patients with glioblastoma to evaluate the safety and efficacy of upfront temozolomide with bevacizumab.
A previous study demonstrated that tumor-treating field therapy improves progression-free survival and overall survival among patients with glioblastoma.
Over 75% and 73.9% of VEGFi-naive and patients previously treated with a VEGFi, respectively, had at least 1 grade 3 or worse adverse event.
Adverse event rates were similar in both trial groups, though patients treated with TTFields were much more likely to have mild to moderate skin toxicity.
TTFs can be self-administered at home by patients; this novel radiation treatment is non-ionizing and delivers electrical fields directly to the brain.
First-line nivolumab plus radiotherapy (RT) with or without temozolomide was tolerated by patients with glioblastoma.
At the preplanned interim analysis, the study was discontinued for futility.
Overall, 54% of patients in the non-adjuvant temozolomide arm had disease progression vs 39% of the adjuvant temozolomide arm.
The US Food and Drug Administration granted orphan drug status to SurVaxM for patients with glioblastoma.
Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.
New immunotherapeutic approaches, such as dendritic cell vaccination, may be effective for treating this rare brain cancer, which is associated with dismal survival rates.
Researchers are attempting to determine the clinical efficacy of ICT-107, a dendritic cell vaccine, among patients with newly diagnosed glioblastoma.
Height, but not body mass index, may be associated with risk of glioblastoma multiforme, the most aggressive form of brain cancer, and other glioma subtypes.
Adding Tumor Treating Fields (TTFields) to maintenance temozolomide significantly prolongs both median and long-term survival.
Onartuzumab does not improve clinical outcomes for patients with glioblastoma when given with bevacizumab.
View detailed drug regimens for the treatment of brain cancer, including treatments such as temozolomide, carboplatin, and methotrexate.
The U.S. Food and Drug Administration (FDA) approved Novocure's premarket approval (PMA) supplement application for the second generation Optune System, which is intended for the treatment of glioblastoma.
Researchers have developed a new method to quantitatively screen cell migration responses of glioma cells to platelet-derived growth factor (PDGF).
BRCA1 protein expression may be an important predictive biomarker of overall survival in glioblastoma multiforme (GBM).
The FDA has approved expanded indication for the Optune device to treat patients with newly diagnosed glioblastoma multiforme.
No differences in overall survival time and quality of life in elderly and/or frail patients with newly diagnosed glioblastoma multiforme.
A retrospective analysis showed that first-line bevacizumab treatment may provide overall survival in glioblastoma.
Patients with low-grade glioma were found to tolerate proton radiation therapy without difficultly.
Glioblastoma patients who developed bevacizumab-induced hypertension experienced increased survival.
Gliomas classified by tumor markers were characterized by distinct mechanisms of pathogenesis, ages at onset and overall survival.
Tumor Treating Fields improved progression-free survival and overall survival in patients with newly diagnosed glioblastoma.
Long-term data do not support efficacy of primary temozolomide monotherapy versus radiotherapy in anapestic glioma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Changes in Renal Cell Carcinoma Pathologic Staging and Histologic Grading
- Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo
- CD19 CAR T-Cell Therapies: "Expect an Evolution"
- Hypofractionated WBI Found Noninferior to Conventionally Fractionated WBI
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified